Enovis Corporation Reports Strong Sales Growth Amid Challenges

Enovis Corporation ( (ENOV) ) has released its Q4 earnings. Here is a breakdown of the information Enovis Corporation presented to its investors.

Enovis Corporation, a medical technology company focused on innovation and growth, develops solutions that improve patient outcomes and transform workflows in orthopedics and beyond. In its latest earnings report, Enovis announced a significant 23% growth in fourth-quarter sales, driven by strong performance in its Reconstructive segment and successful integration of the Lima acquisition. Despite impressive sales growth, the company reported a net loss due to a substantial goodwill impairment charge, reflecting challenges in stock price and market capitalization. Key financial metrics for the fourth quarter included adjusted EBITDA of $113 million, representing a 20% margin, and adjusted earnings per share of $0.98. For the full year, Enovis achieved net sales of $2.1 billion, with a net loss from continuing operations of $827 million. Looking ahead, Enovis projects revenue growth of 6-6.5% for 2025, with expected revenues between $2.19 billion and $2.22 billion and adjusted EBITDA of $405-415 million. The company remains optimistic about its future, with new product launches anticipated to drive growth.